Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Walmart Inc.
WMTConsumer StaplesGenerated Aug 19, 2026, 11:19 PM UTC
WMT (Walmart Inc.) analytical snapshot. Revenue grew +4.7% YoY to $713.16B. 5-year revenue CAGR +4.5%; 10y CAGR +4.4%. Net margin at 3.07% (expanding ▲). Market cap $909.61B at $114.30 per share. Trailing P/E 41.87, P/S 1.28, P/B 9.64. EV/Operating income ≈ 31.42 (EV $937.05B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -8 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest quarterly report (10-Q) filed May 29, 2026. 4 recent 8-K material-event filings in the index. Recent insider Form 4s: 0 buy vs 0 sell transactions.
- Latest quarterly report (10-Q) filed May 29, 2026.
- 4 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Walmart Inc.; broad institutional reporting.
- Recent filers include Silver Grove Financial Group, Inc., Wiser Advisor Group LLC, Trivant Custom Portfolio Group, LLC.
- 4 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 16 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| Silver Grove Financial Group, Inc. | 13F-HR | Feb 13, 2026 |
| Wiser Advisor Group LLC | 13F-HR | May 16, 2024 |
| Trivant Custom Portfolio Group, LLC | 13F-HR | Apr 21, 2025 |
| Silver Grove Financial Group, Inc. | 13F-HR | Feb 17, 2026 |
| Saranac Partners Ltd | 13F-HR | Dec 5, 2025 |
| Date | Form | Description |
|---|---|---|
| Jun 5, 2026 | 8-K | 8-K |
| May 21, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Mar 27, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Operating cash flow exceeds net income: OCF is 1.90x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $680.99B | $713.16B | $32.18B | +4.7% |
| Operating income | $29.35B | $29.82B | $477.0M | +1.6% |
| Net income | $19.44B | $21.89B | $2.46B | +12.6% |
| Operating cash flow | $36.44B | $41.56B | $5.12B | +14.1% |
| Capex | $23.78B | $26.64B | $2.86B | +12.0% |
| Total assets | $260.82B | $284.67B | $23.84B | +9.1% |
| Long-term debt | $36.00B | $38.17B | $2.17B | +6.0% |
| Cash & equivalents | $9.04B | $10.73B | $1.69B | +18.7% |
| Stockholders equity | $91.01B | $99.62B | $8.60B | +9.5% |
| Inventory | $56.44B | $58.85B | $2.42B | +4.3% |
| Accounts receivable | $4.40B | $4.90B | $500.0M | +11.4% |
| SG&A expense | $139.88B | $147.94B | $8.06B | +5.8% |
| Interest expense | $2.25B | $2.32B | $69.0M | +3.1% |
| Type | Concepts |
|---|---|
| Removed | AccountsReceivableNet, AccrualForTaxesOtherThanIncomeTaxesCurrent, AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AdvertisingExpense, AllocatedShareBasedCompensationExpense, CommonStockParOrStatedValuePerShare, CommonStockSharesAuthorized, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit |
Fundamentals
Revenue grew +4.7% YoY to $713.16B. 5-year revenue CAGR +4.5%; 10y CAGR +4.4%. Net margin at 3.07% (expanding ▲).
- Revenue grew +4.7% YoY to $713.16B.
- 5-year revenue CAGR +4.5%; 10y CAGR +4.4%.
- Net margin at 3.07% (expanding ▲).
- Return on equity 21.98%, ROA 7.69%, ROIC 21.65%.
- Gross margin 0.00%, operating margin 4.18%.
- Free cash flow margin 2.09% ($14.92B).
- Net income up ▲ +12.6% YoY.
- Debt/equity 0.40, current ratio 0.77, net debt $27.44B.
- Asset turnover 2.46 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2025 | $680.99B | +5.1% | 0.00 | 4.31 | 2.85 | $12.66B | 21.36 |
| 2026 | $713.16B | +4.7% | 0.00 | 4.18 | 3.07 | $14.92B | 21.98 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jul 31, 2024 | $169.34B | +4.8% | — | 2.66% |
| Oct 31, 2024 | $169.59B | +5.5% | +0.1% | 2.70% |
| Apr 30, 2025 | $165.61B | +2.5% | -2.3% | 2.71% |
| Jul 31, 2025 | $177.40B | +4.8% | +7.1% | 3.96% |
| Oct 31, 2025 | $179.50B | +5.8% | +1.2% | 3.42% |
| Apr 30, 2026 | $177.75B | +7.3% | -1.0% | 3.00% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $909.61B at $114.30 per share. Trailing P/E 41.87, P/S 1.28, P/B 9.64. EV/Operating income ≈ 31.42 (EV $937.05B).
- Market cap $909.61B at $114.30 per share.
Price & Technicals
Price $114.30 — downtrend (below 200-DMA); 1-month momentum positive. RSI(14) 65.50.
- Price $114.30 — downtrend (below 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 0.40 (moderate). Liquidity current ratio 0.77 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -8
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Walmart Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket regime: Risk-on · Supportive..
Peer comparison
Defensive groupHow WMT stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT● you | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |